Quarterly ResultMay 15, 2026, 04:12 PM
Allarity Therapeutics Q1 Net Loss $(2.75)M; Secures $20M in Promissory Notes
AI Summary
Allarity Therapeutics reported a net loss of $(2.75) million for the first quarter of 2026, a slight increase from $(2.73) million in the prior year, with a basic and diluted loss per share of $(0.17). The company significantly increased its cash position by securing $20.0 million through new promissory notes, bringing total cash and restricted cash to $29.8 million. This capital infusion is expected to fund operations for at least the next twelve months, despite ongoing negative cash flows from operations.
Key Highlights
- Net loss for Q1 2026 was $(2.75) million, compared to $(2.73) million in Q1 2025.
- Basic and diluted net loss per common share was $(0.17) for Q1 2026, down from $(0.25) in Q1 2025.
- Total revenue for Q1 2026 was $25 thousand, up from $0 in Q1 2025.
- Secured $20.0 million in gross proceeds from new unsecured and secured promissory notes in March 2026.
- Cash and cash equivalents increased to $19.81 million, and restricted cash to $10.0 million as of March 31, 2026.
- Net cash used in operating activities was $(4.49) million for Q1 2026, compared to $(2.69) million in Q1 2025.
- Repurchased 264,000 shares for $262,036 under a new $5 million share repurchase program.
- Total stockholders' equity decreased to $6.92 million as of March 31, 2026, from $9.83 million at December 31, 2025.
Price Impact
More from ALLR